

Sun Pharmaceutical Industries Limited

Sun House, Plot No. 201 B/1,
Western Express Highway, Goregaon (E),
Mumbai – 400 063, Maharashtra, INDIA.
Tel.: (91-22) 4324 4324
Fax: (91-22) 4324 4343
Website: www.sunpharma.com
Email: secretarial@sunpharma.com
CIN: L24230GJ1993PLC019050



10 April, 2025

National Stock Exchange of India Limited
Scrip Symbol: SUNPHARMA

BSE Limited
Scrip Code: 524715

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Order Vacating Preliminary Injunction on LEQSELVI™

On 09 April 2025, the U.S. Court of Appeals for the Federal Circuit held an oral argument on the Company's appeal of the U.S. District Court for the District of New Jersey's decision that previously granted a preliminary injunction delaying the Company's launch of LEQSELVI™ (deuruxolitinib) in the United States. Shortly after the oral argument concluded, on 09 April 2025, the U.S. Court of Appeals for the Federal Circuit ruled in favour of the Company and vacated the preliminary injunction effective immediately. While the litigation between Incyte Corporation and the Company continues, the preliminary injunction is no longer in effect.

The Company is no longer under a court order that delays or restricts the Company from launching LEQSELVI™. The Company will disclose LEQSELVI™ launch plans in due course of time.

This is further to our intimation dated [02 November 2024](#).

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)
Company Secretary and Compliance Officer
ICSI Membership No.: A23983